Ceribell, Inc. (CBLL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.85 per share a year ago.
CeriBell, Inc. (CBLL) Expected to Beat Earnings Estimates: Should You Buy?
CeriBell, Inc. (CBLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Scott Blumberg - Chief Financial Officer Xingjuan Chao - Co-Founder, President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joshua Thomas Jennings - TD Cowen, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Robert Justin Marcus - JPMorgan Chase & Co, Research Division Travis Lee Steed - BofA Securities, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Brian Johnston - Gilmartin Group LLC Operator Ladies and gentlemen, thank you for standing by.
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q1 2025 Earnings Call.
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
Ceribell secures FDA clearance for Clarity algorithm in pediatric patients, expanding rapid seizure detection capabilities and enhancing critical care efficiency.
CeriBell, Inc. (CBLL) Q4 2024 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jennings - TD Cowen William Plovanic - Canaccord Genuity Corp. Operator Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q4 2024 Earnings Call.
CeriBell: A Leader In AI-Powered Seizure Detection
AI is revolutionizing clinical diagnostics, achieving high accuracy and speed in detecting diseases like Crohn's, fatty liver, coronary artery disease, sepsis, and cancer. CeriBell's AI-powered EEG system offers rapid seizure diagnosis, significantly reducing setup time and ICU stays, thus lowering patient morbidity, mortality, and healthcare costs. Clarity Pro algorithm, FDA-approved in 2023, enhances non-convulsive seizure diagnosis, enabling faster response by ancillary healthcare workers and improving clinical outcomes.
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook
Initiating coverage on CeriBell with a "Buy" rating, citing a promising growth outlook and a 24-month investment horizon. CeriBell's Ceribell System, an AI-powered EEG platform, shows strong revenue growth and high gross margins, indicating robust cash flow potential. The company targets a $2 billion addressable market, with plans for geographic expansion and diversification into other neurological conditions like delirium and ischemic stroke.
CeriBell: An Interesting EEG Play Going Public
CeriBell's IPO was highly successful, with shares rising 60%, but I'm cautious about investing after such a significant price increase. The company offers a revolutionary EEG platform for neurological conditions, showing strong growth while still incurring substantial losses. Despite impressive revenue growth, operating losses have increased so far in 2024, as the company has enough cash to sustain these losses.
Ceribell's stock indicates up 35% in trading debut after pricing IPO at top of range
Ceribell Inc., a medical-device maker that uses artificial intelligence to monitor patient seizures, was on track for a strong trading debut Friday, after its initial public offering priced at the top of its proposed range.
